<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608760</url>
  </required_header>
  <id_info>
    <org_study_id>Interventional</org_study_id>
    <nct_id>NCT04608760</nct_id>
  </id_info>
  <brief_title>Prevention of Acute Pancreatitis After Endoscopic Interventions</brief_title>
  <official_title>Prevention of Acute Pancreatitis After Endoscopic Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitebsk State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vitebsk State Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to develop a method for the prevention of acute pancreatitis after&#xD;
      minimally invasive interventions of the bile ducts using a drug regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, single-center study is planned to identify the most effective drug&#xD;
      regimen in order to prevent the development of acute pancreatitis after transpapillary&#xD;
      interventions of the bile ducts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the level of inflammation and pain, assessment of severity according to the Ranson scale and Krasnogorov at 1 week</measure>
    <time_frame>1 week</time_frame>
    <description>Summ points 0 - pancreatitis, 1 - mild pancreatitis, 2 - severe pancreatitis</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cholangiolitis</condition>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Meksibel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous 0.1 30 minutes before the procedure and 0.1 once a day for 3 days after the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indometacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Into the rectum 1 hour before the procedure and 1 candle 1 time a day for 3 days after the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloksicam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous 15 mg 30 minutes before the procedure and 15 mg once a day for 3 days after the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oktride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous 3 ml 30 minutes before the procedure and 3 ml once a day for 3 days after the procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meksibel</intervention_name>
    <description>2 ml solution</description>
    <arm_group_label>Indometacin</arm_group_label>
    <arm_group_label>Meksibel</arm_group_label>
    <arm_group_label>Meloksicam</arm_group_label>
    <arm_group_label>Oktride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with cholangiolithiasis.&#xD;
&#xD;
          2. Patients with benign formations of the bile ducts.&#xD;
&#xD;
          3. Patients with malignant formations of the bile ducts.&#xD;
&#xD;
          4. Patients with extrahepatic bile duct cysts.&#xD;
&#xD;
          5. Patients with biliary hypertension of unknown etiology.&#xD;
&#xD;
          6. Patients with cholangitis.&#xD;
&#xD;
          7. Patients with extrahepatic bile duct strictures.&#xD;
&#xD;
          8. Patients suffering from oncopathology of the head of the pancreas, complicated by&#xD;
             obstructive jaundice.&#xD;
&#xD;
          9. Patients with malignant pathology of the pancreas.&#xD;
&#xD;
         10. Patients with benign pancreatic pathology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ASA scale&gt; III (severe concomitant cardiovascular pathology)&#xD;
&#xD;
          2. Severe pathology of the respiratory system.&#xD;
&#xD;
          3. Acute period of myocardial infarction.&#xD;
&#xD;
          4. Acute period of cerebral infarction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yury Arlouski, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vitebsk State Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VSMU</name>
      <address>
        <city>Vitebsk</city>
        <zip>210009</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholangiolithiasis, endoscopic, acute pancreatitis, cholangiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

